...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer
【24h】

Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer

机译：癌症患者心包缺口经皮的安全性和结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Malignancy is a common cause of pericardial effusions. The findings, immediate safety and longer-term outcomes of pericardiocentesis are less well defined. We reviewed the cases of all patients with malignancy that underwent pericardiocentesis at our institution over a 10-year period. From January 1, 2007 to December 31, 2016, 171 patients with cancer underwent echo-guided pericardiocentesis. A total of 53% were male with a mean age of 60 ± 15 years. The average volume drained was 485 (IQR 350 to 719) ml. The procedure was technically successful in 170/171 (99.4%) of patients without significant complications; there were no procedure-related deaths. A total of 20% had hemorrhagic, 48% had serosanguinous, and 31% serous pericardial effusions. The type of effusion was not associated with outcome. Cytology (measured in 164) was positive in 58% and only weakly related to outcome (median survival nine versus 18 weeks, p?=?0.04). Per our institutional practice, a pericardial catheter was left in place until there were less than 50 ml of net drainage in 24 hours (average 3 ± 2 days). A total of 135 patients had metastatic carcinoma, 23 patients had lymphoma or chronic leukemia and 4 metastatic sarcoma. Patients with either lymphoma or chronic leukemia had better survival than those with carcinoma or sarcoma (median survival 102 vs 12 weeks, p < 0.0001) with a 46% vs 3% 5-year survival, p < 0.0001). Echoguided pericardiocentesis with extended pericardial catheter placement is safe and effective in cancer patients with pericardial effusions. However, overall outcomes are poor in cancer patients with pericardial effusions that required drainage, particularly in those with carcinoma or sarcoma.
机译：恶性是心包积液的常见原因。心包穿刺术的发现，立即安全性和长期结果不太明确。我们审查了在10年期间在我们的机构接受了心包中的患者的所有患者。从2007年1月1日至2016年12月31日，171例癌症患者接受了回声引导的心膜膜穿刺术。共有53％的男性是男性，平均年龄为60±15年。排水的平均体积为485（IQR 350至719）mL。该程序在170/171（99.4％）的患者中在技术上是成功的，没有显着并发症;没有与程序相关的死亡。总共20％出血，48％有血管致血清，浆膜心包有31％。积分的类型与结果无关。细胞学（在164年测量）在58％的阳性下阳性，只与结果弱（中位数生存九与18周，p？= 0.04）。根据我们的制度实践，将心包导管留下，直到24小时内净排水少于50毫升（平均3±2天）。共有135名患者有转移性癌，23例患者有淋巴瘤或慢性白血病和4种转移性肉瘤。淋巴瘤或慢性白血病患者具有比癌症或肉瘤（中位存活102 vs 12周，P <0.0001）的存活率更好的存活率，具有46％vs 3％5年生存，P <0.0001）。具有延长的心包导管展示位置的echoguided心包内膜穿刺术在癌症患者中是安全可有效的心包患者。然而，癌症患者的整体结果是患者患者的患者，这些患者需要引流，特别是在癌症或肉瘤的那些中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号